Display options
Cite
Doi T, Yamamoto N, Naito Y, et al. Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer Med. 2021;10(19):6579-6589doi: 10.1002/cam4.4110.
Doi, T., Yamamoto, N., Naito, Y., Kuboki, Y., Koyama, T., Piao, Y., Tsujimoto, N., Asou, H., Inoue, K., & Kondo, S. (2021). Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer medicine, 10(19), 6579-6589. https://doi.org/10.1002/cam4.4110
Doi, Toshihiko, et al. "Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study." Cancer medicine vol. 10,19 (2021): 6579-6589. doi: https://doi.org/10.1002/cam4.4110
Doi T, Yamamoto N, Naito Y, Kuboki Y, Koyama T, Piao Y, Tsujimoto N, Asou H, Inoue K, Kondo S. Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer Med. 2021 Oct;10(19):6579-6589. doi: 10.1002/cam4.4110. Epub 2021 Sep 09. PMID: 34499416; PMCID: PMC8495281.
Copy Download .nbib Format: NLM
Share it on

Cancer Med. 2021 Oct;10(19):6579-6589. doi: 10.1002/cam4.4110. Epub 2021 Sep 09.

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study.

Cancer medicine

Toshihiko Doi, Noboru Yamamoto, Yoichi Naito, Yasutoshi Kuboki, Takafumi Koyama, Yongzhe Piao, Naoto Tsujimoto, Hiroya Asou, Koichi Inoue, Shunsuke Kondo

Affiliations

  1. National Cancer Center Hospital East, Chiba, Japan.
  2. Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  3. Eli Lilly Japan K.K, Kobe, Japan.

PMID: 34499416 PMCID: PMC8495281 DOI: 10.1002/cam4.4110

Abstract

This phase 1, multi-center, nonrandomized, open-label, dose-escalation study consisted of Part A wherein merestinib 80 or 120 mg (40-mg tablets) was administered orally QD during a 28-day cycle to patients diagnosed with solid tumors and Part B wherein merestinib 80 mg (40-mg tablets) was administered orally QD, and cisplatin 25 mg/m

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Keywords: biliary tract neoplasms; carcinoma; metastasis; phosphotransferases; toxicity

References

  1. Cancer Treat Rev. 2013 Nov;39(7):793-801 - PubMed
  2. Invest New Drugs. 2013 Aug;31(4):833-44 - PubMed
  3. Lancet Oncol. 2015 Aug;16(8):967-78 - PubMed
  4. Liver Int. 2019 May;39 Suppl 1:19-31 - PubMed
  5. Clin Transl Oncol. 2015 Dec;17(12):982-7 - PubMed
  6. Int J Cancer. 2013 Oct 1;133(7):1664-71 - PubMed
  7. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  8. Clin Lung Cancer. 2019 May;20(3):e317-e328 - PubMed
  9. J Clin Invest. 2002 Apr;109(7):857-62 - PubMed
  10. Trends Cancer. 2018 Feb;4(2):94-97 - PubMed
  11. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7 - PubMed
  12. Oncologist. 2019 Sep;24(9):e930-e942 - PubMed
  13. Br J Cancer. 2011 Jun 28;105(1):131-8 - PubMed
  14. Chin Clin Oncol. 2016 Oct;5(5):61 - PubMed
  15. Clin Cancer Res. 2006 Jun 15;12(12):3657-60 - PubMed
  16. Oncologist. 2008 Apr;13(4):415-23 - PubMed
  17. Eur J Cancer. 2008 Mar;44(5):641-51 - PubMed
  18. Science. 2007 May 18;316(5827):1039-43 - PubMed
  19. Yonsei Med J. 2013 Jan 1;54(1):1-14 - PubMed
  20. Cancer Med. 2021 Oct;10(19):6579-6589 - PubMed
  21. Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 - PubMed
  22. Nature. 1984 Sep 6-11;311(5981):29-33 - PubMed
  23. Jpn J Clin Oncol. 2020 Aug 4;50(8):859-866 - PubMed

Publication Types

Grant support